Trial Condition(s):

Hyperphosphatemia

Fosrenol post-marketing surveillance for hemodialysis in Japan (FOSRENOL-HD)

Bayer Identifier:

15077

ClinicalTrials.gov Identifier:

NCT01419327

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in hemodialysis who received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.

Inclusion Criteria
-  Patients undergoing hemodialysis who received Fosrenol for hyperphosphatemia
Exclusion Criteria
-  Patients who are contraindicated based on the product label

Trial Summary

Enrollment Goal
3267
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Fosrenol (Lanthanum Carbonate, BAY77-1931)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design